
Mvasi by Amgen is the First FDA Approved Cancer Biosimilar
News/Press Release, Thought LeadershipFDA Approves the First Cancer Biosimilar Mvasi by Amgen is Hitting the US Market Yesterday the FDA announced that Amgens biosimilar to Avastin, known as Mvasi (bevacizumab-awwb) was approved for five different types of cancer: Non-squamous non-small cell lung cancer (NSCLC) – in combination with chemotherapy Metastatic colorectal cancer (mCRC) – in combination with chemotherapy Glioblastoma Metastatic renal […]